FIELD: chemistry.
SUBSTANCE: invention relates to a new crystalline polymorphic modification of a monohydrate of mon-sodium salt of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid (ibandronate) of formula 1, used for controlling hypercalcemia. formula 1.
EFFECT: obtaining a new crystalline modification of biologically active compound.
14 cl, 6 dwg, 7 ex
Title | Year | Author | Number |
---|---|---|---|
IBANDRONATE POLYMORPH B | 2006 |
|
RU2387661C2 |
CRYSTALLINE FORM OF ASENAPINE MALEATE | 2006 |
|
RU2405786C2 |
CRYSTALLINE MODIFICATIONS OF HYDROCHLORIDE (-)-(1R, 2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)PHENOL | 2005 |
|
RU2423345C2 |
BISPHOSPHONATE-CONTAINING PHARMACEUTICAL PARENTERAL COMPOSITION | 2001 |
|
RU2238736C2 |
ROMIDEPSIN SOLID FORMS AND USE THEREOF | 2011 |
|
RU2607634C2 |
CRYSTALLINE FORMS OF MONOSODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | 2008 |
|
RU2476440C2 |
CRYSTALLINE MODIFICATIONS | 2005 |
|
RU2400479C2 |
3-[2-(DIMETHYLAMINO)METHYL-(CYCLOHEX-1-YL)]PHENOL MALEATE AND ITS CRYSTALLINE FORMS | 2006 |
|
RU2434845C2 |
FORM VI OF ATORVASTATIN CALCIUM AND ITS HYDRATES | 2002 |
|
RU2294924C2 |
SOLID FORMS OF ORTATAXEL | 2009 |
|
RU2488586C2 |
Authors
Dates
2009-09-27—Published
2006-01-24—Filed